Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Gritstone and bluebird bio enter cell therapy partnership

Executive Summary

Gritstone Oncology agreed to use its EDGE personalized neoantigen platform to provide ten tumor-specific targets (and T-cell receptors (TCRs) directed to those targets) for cell therapy and gene editing firm bluebird bio Inc.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register